Previous 10 | Next 10 |
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...
EQUALISE Phase 1b Study in lupus nephritis fully enrolled – topline data in early 2024 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abs...
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally del...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual analyst and investor day on Monday, October 16, 2023 at 9 a.m. PT / 12:00 p.m. ET. D...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the JonesTrading 2023 Healthcare Summit taking place October 9 - 11 at the Eden Roc hotel in...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference...
Revenue Increases Over 50% - EBITDA on Track to Profitability - New $4M Credit Facility TORONTO, ON / ACCESSWIRE / August 29, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in AI and geospatial data driven software and solutions, announced its financial results today for t...
2023-08-09 17:52:25 ET Equillium press release ( NASDAQ: EQ ): Q2 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $9.12M beats by $2.98M . For further details see: Equillium GAAP EPS of -$0.10 beats by $0.06, revenue of $9.12M beats by $2.98M
News, Short Squeeze, Breakout and More Instantly...
Equillium Inc. Company Name:
EQ Stock Symbol:
NASDAQ Market:
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday. The Dow traded up 0.53% to 38,774.55 ...
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...